

Piet L C M Van Riel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1302320/publications.pdf>

Version: 2024-02-01

68
papers

7,466
citations

279798

23
h-index

102487

66
g-index

71
all docs

71
docs citations

71
times ranked

12123
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 20-33.	0.9	104
2	Does Etanercept Biosimilar Prescription in a Rheumatology Center Bend the Medication Cost Curve?. <i>Journal of Rheumatology</i> , 2021, 48, 1803-1809.	2.0	7
3	EULAR definition of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 31-35.	0.9	224
4	Co-Design of a Disease Activity Based Self-Management Approach for Patients with Rheumatoid Arthritis. <i>Mediterranean Journal of Rheumatology</i> , 2021, 31, 21.	0.8	2
5	Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit. <i>RMD Open</i> , 2021, 7, e001724.	3.8	12
6	Telemedicine in the management of rheumatoid arthritis: maintaining disease control with less health-care utilization. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkaa079.	0.7	27
7	The Development and Evaluation of Personalized Training in Shared Decision-making Skills for Rheumatologists. <i>Journal of Rheumatology</i> , 2020, 47, 290-297.	2.0	3
8	Is radiographic progression a downside of stopping TNF-inhibitor in RA patients with low disease activity, if this is followed by flare? A sub-study of the POET-US trial. <i>Rheumatology</i> , 2020, 59, 1170-1171.	1.9	0
9	Smoking cessation is associated with lower disease activity and predicts cardiovascular risk reduction in rheumatoid arthritis patients. <i>Rheumatology</i> , 2020, 59, 1997-2004.	1.9	29
10	One-year results after transitioning from etanercept originator to biosimilar in a setting promoting shared decision-making in rheumatology. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa042.	0.7	8
11	Two parallel short forms to measure disease- and treatment-associated knowledge in rheumatoid arthritis: application of item response theory. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa012.	0.7	0
12	Strategies for implementation of guideline recommended cardiovascular risk management for patients with rheumatoid arthritis: results from a questionnaire survey of expert rheumatology centers. <i>Rheumatology International</i> , 2020, 40, 523-527.	3.0	7
13	Disease activity-based management of rheumatoid arthritis in Dutch daily clinical practice has improved over the past decade. <i>Clinical Rheumatology</i> , 2020, 39, 1131-1139.	2.2	2
14	Prediction of cardiovascular events in rheumatoid arthritis using risk age calculations: evaluation of concordance across risk age models. <i>Arthritis Research and Therapy</i> , 2020, 22, 90.	3.5	11
15	Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment. <i>BMC Rheumatology</i> , 2019, 3, 3.	1.6	4
16	Patient Self-Management and Tracking. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 187-195.	1.9	35
17	SAT0109...SMOKING CESSATION IN PATIENTS WITH RA IS ASSOCIATED WITH REDUCED CVD EVENT RATES AND IMPROVED LIPID PROFILES AND PREDICTS LOWER RA DISEASE ACTIVITY. , 2019, , .		0
18	Biosimilars in the management of chronic inflammatory diseases: The Dutch experience. <i>Mediterranean Journal of Rheumatology</i> , 2019, 30, 76.	0.8	5

#	ARTICLE	IF	CITATIONS
19	Impact of Stopping Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis Patientsâ€™ Burden of Disease. <i>Arthritis Care and Research</i> , 2018, 70, 516-524.	3.4	10
20	Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 48-54.	0.9	194
21	Implementation of the EULAR cardiovascular risk management guideline in patients with rheumatoid arthritis: results of a successful collaboration between primary and secondary care. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 480-483.	0.9	20
22	Development of an item bank to measure factual disease and treatment related knowledge of rheumatoid arthritis patients in the treat to target era. <i>Patient Education and Counseling</i> , 2018, 101, 67-73.	2.2	5
23	Comparison of the construct validity and reproducibility of four different types of patient-reported outcome measures (PROMs) in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2018, 37, 3191-3199.	2.2	19
24	An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity. <i>Arthritis and Rheumatology</i> , 2018, 70, 1557-1564.	5.6	17
25	Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment. <i>PLoS ONE</i> , 2018, 13, e0192425.	2.5	17
26	Tailored, Therapist-Guided Internet-Based Cognitive Behavioral Therapy Compared to Care as Usual for Patients With Rheumatoid Arthritis: Economic Evaluation of a Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2018, 20, e260.	4.3	8
27	Exercise participation has increased in patients with Rheumatoid Arthritis: A cross-sectional comparison between two Dutch RA cohorts. <i>Mediterranean Journal of Rheumatology</i> , 2018, 29, 199-206.	0.8	2
28	Cost-Effectiveness of Cardiovascular Screening in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2017, 69, 175-182.	3.4	8
29	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.9	3,366
30	A pilot study of CXCL8 levels in crystal proven gout patients during allopurinol treatment and their association with cardiovascular disease. <i>Joint Bone Spine</i> , 2017, 84, 709-713.	1.6	6
31	Limited value for ultrasonography in predicting flare in rheumatoid arthritis patients with low disease activity stopping TNF inhibitors. <i>Rheumatology</i> , 2017, 56, 1560-1565.	1.9	19
32	Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries. <i>Rheumatology</i> , 2017, 56, 1102-1110.	1.9	100
33	Influence of route of administration/drug formulation and other factors on adherence to treatment in rheumatoid arthritis (pain related) and dyslipidemia (non-pain related). <i>Current Medical Research and Opinion</i> , 2017, 33, 1231-1246.	1.9	11
34	Evaluating quality of care in rheumatoid arthritis: the patient perspective. <i>RMD Open</i> , 2017, 3, e000411.	3.8	5
35	Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis. <i>PLoS ONE</i> , 2017, 12, e0174656.	2.5	38
36	Impaired <i>Porphyromonas gingivalis</i> -Induced Tumor Necrosis Factor Production by Dendritic Cells Typifies Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 795-804.	5.6	10

#	ARTICLE	IF	CITATIONS
37	Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2016, 68, 1810-1817.	5.6	70
38	Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools. <i>RMD Open</i> , 2016, 2, e000302.	3.8	57
39	A different perspective: Inflammatory rheumatic diseases and other organs. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 787-788.	3.3	1
40	Patients with Systemic Sclerosis/polymyositis Overlap Have a Worse Survival Rate Than Patients Without It. <i>Journal of Rheumatology</i> , 2016, 43, 1838-1843.	2.0	21
41	Effectiveness of Tumor Necrosis Factor Inhibitors in Combination with Various csDMARD in the Treatment of Rheumatoid Arthritis: Data from the DREAM Registry. <i>Journal of Rheumatology</i> , 2016, 43, 1787-1794.	2.0	12
42	Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. <i>Arthritis Research and Therapy</i> , 2016, 18, 50.	3.5	37
43	The influence of patient perceptions of disease on medication intensification in daily practice. <i>Rheumatology</i> , 2016, 55, 1938-1945.	1.9	9
44	A multidimensional 'path analysis' model of factors explaining fatigue in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 200-6.	0.8	13
45	The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S40-S44.	0.8	100
46	Monitoring rheumatoid arthritis using an algorithm based on patient-reported outcome measures: a first step towards personalised healthcare. <i>RMD Open</i> , 2015, 1, e000114.	3.8	14
47	Predictors of satisfactory improvements in pain for patients with early rheumatoid arthritis in a treat-to-target study. <i>Rheumatology</i> , 2015, 54, 1080-1086.	1.9	12
48	Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. <i>Arthritis Research and Therapy</i> , 2015, 17, 134.	3.5	57
49	Quality in rheumatoid arthritis care. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 664-679.	3.3	11
50	Validity and measurement precision of the PROMIS physical function item bank and a content validity-driven 20-item short form in rheumatoid arthritis compared with traditional measures. <i>Rheumatology</i> , 2015, 54, kev265.	1.9	28
51	Personalizing Treatment Targets in Rheumatoid Arthritis by Using a Simple Prediction Model. <i>Journal of Rheumatology</i> , 2015, 42, 398-404.	2.0	11
52	Assessment of Fatigue in Rheumatoid Arthritis: A Psychometric Comparison of Single-item, Multiitem, and Multidimensional Measures. <i>Journal of Rheumatology</i> , 2015, 42, 413-420.	2.0	18
53	A Simplified Baseline Prediction Model for Joint Damage Progression in Rheumatoid Arthritis: A Step toward Personalized Medicine. <i>Journal of Rheumatology</i> , 2015, 42, 391-397.	2.0	6
54	Effectiveness of TNF inhibitor treatment with various methotrexate doses in patients with rheumatoid arthritis: results from clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e24-e24.	0.9	11

#	ARTICLE	IF	CITATIONS
55	The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 998-1003.	0.9	121
56	Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry. <i>RMD Open</i> , 2015, 1, e000147.	3.8	11
57	The detection of monosodium urate crystals in synovial fluid after long-term and varying storage conditions. <i>Joint Bone Spine</i> , 2015, 82, 470-471.	1.6	12
58	Estimation of heritability of different outcomes for genetic studies of TNFi response in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2183-2187.	0.9	27
59	Calibration of the PROMIS Physical Function Item Bank in Dutch Patients with Rheumatoid Arthritis. <i>PLoS ONE</i> , 2014, 9, e92367.	2.5	30
60	Serum Samples That Have Been Stored Long-Term (>10 Years) Can Be Used as a Suitable Data Source for Developing Cardiovascular Risk Prediction Models in Large Observational Rheumatoid Arthritis Cohorts. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	7
61	Burden of disease in treated rheumatoid arthritis patients: Going beyond the joint. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 479-488.	3.4	98
62	Genetics of rheumatoid arthritis contributes to biology and drug discovery. <i>Nature</i> , 2014, 506, 376-381.	27.8	1,974
63	Does stress affect the joints? Daily stressors, stress vulnerability, immune and HPA axis activity, and short-term disease and symptom fluctuations in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1683-1688.	0.9	49
64	Immune responses to stress in rheumatoid arthritis and psoriasis. <i>Rheumatology</i> , 2014, 53, 1844-1848.	1.9	20
65	Determinants Associated with Work Participation in Patients with Established Rheumatoid Arthritis Taking Tumor Necrosis Factor Inhibitors. <i>Journal of Rheumatology</i> , 2014, 41, 1263-1269.	2.0	6
66	Established rheumatoid arthritis: clinical assessments. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007, 21, 807-825.	3.3	13
67	DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2005, 7, 189.	3.5	35
68	Tailored cognitive-behavioral therapy in early rheumatoid arthritis for patients at risk: a randomized controlled trial. <i>Pain</i> , 2002, 100, 141-153.	4.2	239